By Dr Nicola Davies
Epidermolysis bullosa (EB) is a class of rare diseases that result in fragile skin prone to injury and blistering.1 The last week in October is EB Awareness Week – an apt time to build knowledge on this severe condition for which common subtypes are estimated to occur in 1 in every 50,000 births globally across all ethnicities and genders.1
What is Epidermolysis bullosa?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze